SINGAPORE, Aug 14, 2024 – (ACN Newswire via SeaPRwire.com) – ALUXE, cherished for its unwavering commitment to celebrating love and happiness, is delighted to introduce 8 stunning new additions to its exclusive “Lovers” collection. Originally launched in 2023, this exquisite wedding ring collection now embraces new designs that seamlessly blend timeless elegance with contemporary flair. ALUXE […]
HONG KONG, Aug 14, 2024 – (ACN Newswire via SeaPRwire.com) – Nissin Foods Company Limited (“Nissin Foods” or the “Company”, together with its subsidiaries, the “Group”; Stock code: 1475) is pleased to announce that the Company is selected as a constituent to the MSCI Global Micro Cap Index (MSCI Hong Kong Micro Cap Index), with […]
MELBOURNE, Aug 14, 2024 – (ACN Newswire via SeaPRwire.com) – Mark your calendars for an unmissable event! We are thrilled to announce our partnership with the upcoming Modern DevOps Melbourne, taking place on October 8, 2024, at the prestigious Grand Hyatt Melbourne. This event promises to be a cornerstone for industry leaders and innovators in […]
香港, 2024年8月13日 – (亞太商訊 via SeaPRwire.com) – 由香港貿易發展局 （香港貿發局） 主辦、文創產業發展處資助的亞洲時裝界年度盛事 CENTRESTAGE（香港國際時尚匯展），將於9月4至7日（星期三至星期六）假香港會議展覽中心隆重舉行，而開幕時裝騷CENTRESTAGE…
SINGAPORE, Aug 14, 2024 – (ACN Newswire via SeaPRwire.com) – ALUXE, cherished for its unwavering commitment to celebrating love and happiness, is delighted to introduce 8 stunning new additions to its exclusive “Lovers” collection. Originally launched in 2023, this exquisite wedding ring collection now embraces new designs that seamlessly blend timeless elegance with contemporary flair. ALUXE […]
Development Highlights – During the reporting Period, four of the Group’s innovative products were approved for marketing by the National Medical Products Administration of China (“NMPA”), namely Andewei (Benmelstobart Injection), Anboni (Unecritinib capsules), Anluoqing (Envonalkib capsules) and Beilelin (Liraglutide Injection), three of which are national category 1 innovative drugs. – In the first half of […]
重點成果 – 期內，集團共有4個創新產品獲中國國家藥品監督管理局（「NMPA」）批准上市，分別為安得衛（貝莫蘇拜單抗注射液）、安柏尼（富馬酸安奈克替尼膠囊）、安洛晴（枸櫞酸依奉阿克膠囊）和貝樂林（利拉魯肽注射液），其中3個為國家1類創新藥。 – 2024年上半年，集團創新產品收入達到61.3億元…